What if we could use the OTHER 99% for drug discovery...not just the 1%?

In the world of drug discovery, for the most part it hasn't change much in decades. Ross Youngs, CEO of Biosortia Pharmaceuticals is looking to change that with a better understanding of the microbiome.  

The Biosortia technology opens the doors to previous unobtainable drug-like signaling molecules and will impact all therapeutics, agriculture, cosmetics, and other industries.  Importantly - researchers have had less than 1% of this source previously available & that small percentage has still led to more than 50% of the drugs on the shelf - the door is now open to potentially the full 100% of the source (this is World-Changing).     

Pharma's past failures to deliver costing billions of dollars a year in combinatorial chemistry & genomics with few drug on the shelf has resulted in tunnel vision & lack of research adventurism.  Listen in on our conversation. Hear the passion Ross has for this technology and the future of drug discovery.  

Learn more about Biosortia Pharmaceuticals at https://www.biosortia.com/.  

Reach out to Ross on LinkedIn at https://www.linkedin.com/in/rossyoungs/.  

Thanks for listening to the Modern Biopharma Podcast. 

Check us out at http://www.modernbiopharma.com or hit me up on LinkedIn at https://www.linkedin.com/in/talktojesse/.